Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Branebrutinib Treatment in Subjects With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Subjects With Active Rheumatoid Arthritis
Other study identifiers
Sponsor study identifier
Secondary identifiers
EUDRACT_NUMBER
NIH
interventional
119
10 countries
81
Study Start
January 7, 2020
Actual (reported)Primary Completion
December 5, 2022
Actual (reported)Study Completion
December 5, 2022
Actual (reported)Brief Summary
The purpose of this study is to evaluate the safety and effectiveness of treatment with branebrutinib treatment in participants with active systemic Lupus Erythematosus (SLE) or Primary Sjögren's Syndrome (pSS), or branebrutinib treatment followed by open-label abatacept treatment in study participants with active Rheumatoid Arthritis (RA).
Registry Overview
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
- Recruitment status
- completed
- Actual enrollment (reported)
- 119 participants
- Study completion date
December 5, 2022
Actual (reported)- Listed locations
- 10 countries · 81 sites
Trial Relationships
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Study Timeline
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
First Submitted
November 28, 2019
Actual (reported)First Posted
December 5, 2019
Actual (reported)Study Start
January 7, 2020
Actual (reported)Primary Completion
December 5, 2022
Actual (reported)Study Completion
December 5, 2022
Actual (reported)Results Posted
January 16, 2024
Actual (reported)
- Last Updated
- January 16, 2024
- Status Verified
- January 2024
- Results QC Date
- January 12, 2024
- Last Update Submitted
- January 12, 2024